On Nov. 19, 2020, the University of Oxford announced that the ChAdOx1 nCov-2019 coronavirus vaccine had been shown to trigger a robust immune response in healthy adults aged 56-69 and those over 70 years of age. The data. published in The Lancet, suggest that one of the groups most vulnerable to serious illness, and death from COVID-19, could build immunity.